Eagle IP is excited to sponsor and participate in IAM’s IPBC Connect, returning to Zoom for a week of high-level discussions involving the world’s leading IP experts. From 22-26 March, IAM hosted more than 20 individual interactive digital sessions, each designed to facilitate the exchange of information and insight, benchmarking and the sharing of the best practice in key areas of strategic IP value creation.

Our VP Jennifer Che spoke as an IP expert at an open discussion forum about Patent Law Update Asia, happening March 23 at 11AM HKT (March 22, 11PM EST for those in North America).

You can register for as many sessions as you like across the week, building your own schedule. Find out more here: httpss://cvent.me/VnkWam?RefId=Sponsor

我们的过去活动

Recommended Insights

CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants

2023年4月12日
At the end of October 2022, the China National Intellectual Property Administration (CNIPA) released a new draft amendment of the Patent Examination Guidelines[1] (hereinafter referred to as the “New Draft”) to the new Chinese Patent Law that came into effect in 2021. We highlight two key amendments below. 1. The starting date for calculating PTA […]

First ever Invalidation decision on an RNAi Invention patent in China

2023年12月4日
Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]

China’s Newest Examination Guidelines: Novelty and Inventive Step for Compounds (Part II)

2021年4月29日
This is Part II of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

2018年11月23日
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]
Top crossarrow-right